Trial · NCT04489420
Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM
NCT04489420, Phase 1, Terminated, Celularity Incorporated
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM. Trials, record NCT04489420. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04489420
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM
- NCT number
- NCT04489420
- Status
- Terminated
- Phases
- Phase 1
- Enrollment
- 3 participants, actual
- Lead sponsor
- Celularity Incorporated
- Conditions
Astrocytoma, Grade IV, Giant Cell Glioblastoma, Glioblastoma Multiforme, Cyclophosphamide, Immunosuppressive Agents, Immunologic Factors, Physiological Effects of Drugs, Molecular Mechanisms of Pharmacological Action, Antiviral Agents, Anti-infective Agents, Analgesics, Non-narcotic, Analgesics, Sensory System Agents, Peripheral Nervous System Agents
- Interventions
- CYNK001-IV, CYNK001-IT
- First posted
- 2020-07-28
- Last updated
- 2022-08-10
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants who experienced a Dose-Limiting Toxicity (DLT) | Day 42 | Defined as the maximum dose safely administered intravenously or Intratumoral for the treatment of patients with GBM. |
| Primary | Adverse Events (AEs) | 1 year | Defined as the number and Severity of Adverse Events |
| Secondary | Overall Response Rate | 1 year | Defined as the proportion of subjects with best overall response of either complete response (CR) or partial response (PR) |
| Secondary | Duration of Response Rate | 1year | Defined as duration from first observation of partial response (PR) or better to the date of disease progression per RANO criteria |
| Secondary | Progression-free survival | 1year | Defined as date of the first CYNK-001 infusion to the date of disease progression per RANO Response Criteria or death (regardless of cause of death), whichever comes first |
| Secondary | Time to porgression | 1year | Defined as the date of the first CYNK-001 infusion to the date of disease progression per RANO Response Criteria, with deaths from causes other than progression censored |
| Secondary | Overall Survival | 1year | Defined as the date of the first CYNK-001 infusion to the date of death |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04489420
GET https://conductscience.org/api/trials/v1/NCT04489420/registered